Neuropace Stock Alpha and Beta Analysis
| NPCE Stock | USD 10.66 0.96 9.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neuropace. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neuropace over a specified time horizon. Remember, high Neuropace's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neuropace's market risk premium analysis include:
Beta 2.47 | Alpha 0.32 | Risk 5.39 | Sharpe Ratio 0.12 | Expected Return 0.65 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neuropace |
Neuropace Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neuropace market risk premium is the additional return an investor will receive from holding Neuropace long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neuropace. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neuropace's performance over market.| α | 0.32 | β | 2.47 |
Neuropace expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neuropace's Buy-and-hold return. Our buy-and-hold chart shows how Neuropace performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Neuropace Market Price Analysis
Market price analysis indicators help investors to evaluate how Neuropace stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neuropace shares will generate the highest return on investment. By understating and applying Neuropace stock market price indicators, traders can identify Neuropace position entry and exit signals to maximize returns.
Neuropace Return and Market Media
The median price of Neuropace for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 7.01 with a coefficient of variation of 12.74. The daily time series for the period is distributed with a sample standard deviation of 0.92, arithmetic mean of 7.21, and mean deviation of 0.68. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 765 shares by Kck Ltd. of Neuropace at 7.5 subject to Rule 16b-3 | 09/20/2024 |
2 | Disposition of 282 shares by Kck Ltd. of Neuropace at 7.54 subject to Rule 16b-3 | 09/23/2024 |
3 | Disposition of 5858 shares by Kck Ltd. of Neuropace at 6.6 subject to Rule 16b-3 | 09/25/2024 |
4 | Disposition of 5821 shares by Kck Ltd. of Neuropace at 6.62 subject to Rule 16b-3 | 09/26/2024 |
5 | Disposition of 5059 shares by Kck Ltd. of Neuropace at 6.63 subject to Rule 16b-3 | 09/27/2024 |
6 | Disposition of 4749 shares by Kck Ltd. of Neuropace at 6.73 subject to Rule 16b-3 | 09/30/2024 |
7 | Disposition of 3843 shares by Kck Ltd. of Neuropace at 6.87 subject to Rule 16b-3 | 10/02/2024 |
8 | Disposition of 5757 shares by Kck Ltd. of Neuropace at 6.9185 subject to Rule 16b-3 | 10/04/2024 |
9 | Disposition of 4910 shares by Kck Ltd. of Neuropace at 6.6573 subject to Rule 16b-3 | 10/07/2024 |
10 | Disposition of 6000 shares by Kck Ltd. of Neuropace at 6.4253 subject to Rule 16b-3 | 10/08/2024 |
11 | Disposition of 3123 shares by Kck Ltd. of Neuropace at 6.1048 subject to Rule 16b-3 | 10/09/2024 |
12 | Disposition of 2504 shares by Kck Ltd. of Neuropace at 6.117 subject to Rule 16b-3 | 10/10/2024 |
13 | Disposition of 2572 shares by Kck Ltd. of Neuropace at 6.3451 subject to Rule 16b-3 | 10/11/2024 |
14 | Disposition of 4031 shares by Kck Ltd. of Neuropace at 6.5393 subject to Rule 16b-3 | 10/14/2024 |
15 | Disposition of 4017 shares by Kck Ltd. of Neuropace at 6.497 subject to Rule 16b-3 | 10/15/2024 |
16 | Disposition of 3294 shares by Kck Ltd. of Neuropace at 6.28 subject to Rule 16b-3 | 10/17/2024 |
17 | Disposition of 3720 shares by Kck Ltd. of Neuropace at 6.0964 subject to Rule 16b-3 | 10/21/2024 |
18 | NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024 | 10/22/2024 |
19 | Disposition of 147 shares by Kck Ltd. of Neuropace at 6.02 subject to Rule 16b-3 | 10/23/2024 |
20 | Disposition of 223991 shares by Kck Ltd. of Neuropace at 5.4513 subject to Rule 16b-3 | 10/25/2024 |
21 | KCK LTD.s Strategic Reduction in NeuroPace Inc Shares | 10/29/2024 |
22 | Disposition of 8842 shares by Orbimed Advisors Llc of Neuropace at 14.01 subject to Rule 16b-3 | 11/08/2024 |
23 | NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance | 11/12/2024 |
24 | Earnings call NeuroPace reports record Q3 revenue, up 28 | 11/13/2024 |
25 | Heres What Analysts Are Forecasting For NeuroPace, Inc. After Its Third-Quarter Results | 11/14/2024 |
26 | Wall Street Analysts Believe NeuroPace Could Rally 54.34 percent Heres is How to Trade | 11/18/2024 |
27 | NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com | 11/21/2024 |
About Neuropace Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neuropace or other stocks. Alpha measures the amount that position in Neuropace has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 8.53 | 6.07 | 7.42 | 9.92 | Days Of Inventory On Hand | 243.02 | 272.12 | 236.61 | 276.82 |
Neuropace Upcoming Company Events
As portrayed in its financial statements, the presentation of Neuropace's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neuropace's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neuropace. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Neuropace
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Neuropace Backtesting, Neuropace Valuation, Neuropace Correlation, Neuropace Hype Analysis, Neuropace Volatility, Neuropace History and analyze Neuropace Performance. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Neuropace technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.